Shots:
- Genentech reports the new 2yrs. data from part 2 of SUNFISH study assessing Evrysdi vs PBO in people aged 2-25 years with Type 2 or Type 3 SMA
- Results: improvement in maintained motor function b/w 12-24mos. as measured by MFM-32; change from baseline in SMAIS score; stabilized motor function after 12mos. as per MFM-32, RULM and HFMSE; increased motor function as measured by RULM and HFMSE b/w 12-24mos.
- Evrysdi is the first and only at home SMA treatment which has proven efficacy across adults, children and infants 2 months and older
Click here to read full press release/ article | Ref: Businesswire | Image: Fortune
The post Genentech Reports Two-Year Data of Evrysdi (risdiplam) for People with Type 2 or Type 3 SMA first appeared on PharmaShots.
